MannKind to acquire scPharmaceuticals for $360m.

MannKind, a biopharmaceutical company, agreed to acquire scPharmaceuticals, a clinical-stage pharmaceutical company focused on advancing cardiorenal care, for $360m. “This acquisition expands our patient-centered brands and highlights MannKind’s dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases. With multiple anticipated product launches and indication expansions, we expect to continue to diversify our revenue streams and accelerate our double-digit growth goals over the next decade,” Michael Castagna, MannKind CEO.